Highly hypofractionated biaxially rotational dynamic radiation therapy ( BROAD ‐ RT ) for high‐risk prostate cancer
Cancer Science · 2025
DOI: 10.1111/cas.16429 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Science, 2025. Verfasst von Rihito Aizawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Radiotherapy, Intensity-Modulated, Radiation Dose Hypofractionation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
To report clinical outcomes following highly hypofractionated biaxially rotational dynamic radiation therapy (BROAD‐RT), a unique radiation therapy method that facilitates non‐coplanar volumetric‐modulated arc therapy (VMAT) without the need to rotate the couch or reposition the patient, for high‐risk prostate cancer (PCa) with simultaneous integrated boost (SIB) for intra‐prostatic dominant lesions (IPDLs), we performed a single‐center prospective pilot study. In this study, patients with high‐risk PCa according to the D'Amico classification or those with cT3aN0M0 PCa were eligible. VMAT was performed using BROAD‐RT, and a dose of 54 Gy in 15 fractions was prescribed for the prostate in combination with SIB for IPDLs at a dose of 57 Gy in 15 fractions. Short‐term neoadjuvant androgen‐deprivation therapy (median: 6.9 months) was conducted. Neither adjuvant androgen‐deprivation therapy nor fiducial marker implantation to the prostate was applied for any patient. In total, 26 patients were registered in this study between August 2018 and November 2020. Their median age was 73 years at the initiation of RT. The median follow‐up period was 49.7 months. The 4‐year cumulative incidence rates of grade 2 late GU and GI toxicities were 15.4 and 3.8%, respectively. No grade 3 or higher acute or late toxicities were observed. The 4‐year biochemical failure‐free survival rates were 87.7%. In conclusion, highly hypofractionated RT using BROAD‐RT for high‐risk PCa with SIB for IPDLs was feasible and facilitated favorable oncological outcomes. Therefore, this approach is considered a promising method to achieve safe dose escalation and shorten the treatment duration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology and Image-Applied Therapy, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Urology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- Department of Radiation Oncology, Kyoto City Hospital, Kyoto, Japan.
- Department of Radiotherapy, Tenri Hospital, Tenri, Japan.
- Department of Radiation Oncology, Kobe City Medical Center General Hospital, Kobe, Japan.
ORCID-Profile: Rihito Aizawa, Kaoru Murakami, Takashi Kobayashi, Takashi Mizowaki
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Aizawa, R., Ogata, T., Goto, T., Nakamura, K., Takayama, K., Ashida, R., Kita, Y., Sumiyoshi, T., Murakami, K., Mizuno, K., Kobayashi, T., & Mizowaki, T. (2025). Highly hypofractionated biaxially rotational dynamic radiation therapy ( BROAD ‐ RT ) for high‐risk prostate cancer. Cancer Science. https://doi.org/10.1111/cas.16429
Vancouver
Aizawa R, Ogata T, Goto T, Nakamura K, Takayama K, Ashida R, et al. Highly hypofractionated biaxially rotational dynamic radiation therapy ( BROAD ‐ RT ) for high‐risk prostate cancer. Cancer Science. 2025. doi:10.1111/cas.16429
BibTeX
@article{Aizawa2025,
author = {Aizawa, Rihito and Ogata, Takashi and Goto, Takayuki and Nakamura, Kiyonao and Takayama, Kenji and Ashida, Ryo and Kita, Yuki and Sumiyoshi, Takayuki and Murakami, Kaoru and Mizuno, Kei and Kobayashi, Takashi and Mizowaki, Takashi},
title = {Highly hypofractionated biaxially rotational dynamic radiation therapy ( BROAD ‐ RT ) for high‐risk prostate cancer},
journal = {Cancer Science},
year = {2025},
doi = {10.1111/cas.16429}
}
EUVIMED